Stockholder Vote Looms for Alzamend Neuro's $25M Preferred Conversion as Nasdaq Deadlines Approach
ALZN sits 98% above its 52-week low of $0.84.
Summary
Alzamend Neuro's preliminary proxy seeks stockholder approval to convert up to $25 million in Series D Preferred Stock into common shares, with new details on conversion mechanics and Nasdaq compliance deadlines.
Key Events · Financing and Capital Events · ALZN
-
Stockholder Vote on $25M Preferred Conversion
Proposal No. 3 seeks approval to convert up to $25 million in Series D Preferred Stock into common shares, with the Investor (Ault Lending) unable to vote its affiliated shares on the proposal.
-
Deeply Dilutive Conversion Formula
Conversion price is the greater of $0.2668 (Floor Price) or 80% of the lowest closing bid price over five trading days, capped at $2.00 — potentially issuing up to 98.4 million shares at the floor price.
-
Nasdaq Equity Rule Deadline
Company must meet Nasdaq's $2.5 million minimum stockholders' equity requirement by September 16, 2026; failure to approve this financing would jeopardize compliance.
-
Independent Director Deficiency
Following the death of independent director Lynne Fahey McGrath on July 20, 2026, the company must appoint a replacement independent director by January 18, 2027 to regain Nasdaq compliance.
Analysis · ALZN · Life Sciences
Stockholders are being asked to approve the conversion of up to $25 million in Series D Preferred Stock into common shares, a deal first disclosed on August 3, 2026. The proxy statement reveals critical new details: the conversion price is tied to a floor of $0.2668 or 80% of the lowest closing bid price over five days, capped at $2.00 — a deeply dilutive structure for existing holders. The filing also discloses that the company must meet Nasdaq's $2.5 million equity requirement by September 16, 2026, and cure its independent director deficiency by January 18, 2027, following the death of director Lynne Fahey McGrath. Failure to approve this proposal would force the company to seek alternative financing on less favorable terms, jeopardizing its Nasdaq listing.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.6% of the 1805 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ALZN was trading at $1.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8M. The 52-week trading range was $0.84 to $2.68. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.